Details for Patent: 9,533,955
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,533,955 protect, and when does it expire?
Patent 9,533,955 protects TREANDA and is included in one NDA.
This patent has seventeen patent family members in eleven countries.
Summary for Patent: 9,533,955
Title: | Solid forms of bendamustine hydrochloride |
Abstract: | Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use. |
Inventor(s): | Cooper; Martin Ian (Foxton, GB), Courvoisier; Laurent D. (Thorndale, PA), Eddleston; Mark (Chillwell, GB), McKean; Robert E. (Chester Springs, PA) |
Assignee: | Cephalon, Inc. (Frazer, PA) |
Application Number: | 15/045,523 |
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 9,533,955
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cephalon | TREANDA | bendamustine hydrochloride | POWDER;IV (INFUSION) | 022249-002 | May 1, 2009 | AP | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | FOR USE IN THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA | See Plans and Pricing | ||
Cephalon | TREANDA | bendamustine hydrochloride | POWDER;IV (INFUSION) | 022249-002 | May 1, 2009 | AP | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | See Plans and Pricing | ||
Cephalon | TREANDA | bendamustine hydrochloride | POWDER;IV (INFUSION) | 022249-001 | Mar 20, 2008 | AP | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | FOR USE IN THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA | See Plans and Pricing | ||
Cephalon | TREANDA | bendamustine hydrochloride | POWDER;IV (INFUSION) | 022249-001 | Mar 20, 2008 | AP | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | See Plans and Pricing | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,533,955
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 072777 | See Plans and Pricing | |||
Canada | 2718939 | See Plans and Pricing | |||
Chile | 2009000742 | See Plans and Pricing | |||
China | 101980698 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |